# Sildenafil for the Prevention of Right Heart Failure Following LVAD Implantation

> **NCT03356353** · PHASE3 · UNKNOWN · sponsor: **University of Calgary** · enrollment: 24 (estimated)

## Conditions studied

- End Stage Heart Failure

## Interventions

- **DRUG:** Sildenafil Citrate

## Key facts

- **NCT ID:** NCT03356353
- **Lead sponsor:** University of Calgary
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-03-12
- **Primary completion:** 2021-09-30
- **Final completion:** 2022-01
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2021-04-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03356353

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03356353, "Sildenafil for the Prevention of Right Heart Failure Following LVAD Implantation". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03356353. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*